Showing 5 posts of 5 posts found.


NHS in Scotland makes rheumatoid arthritis drug available

September 14, 2021
Manufacturing and Production Galapagos UK, NHS, Scotland, filgotinib, rheumatoid arthritis

The Scottish Medicines Consortium (SMC) have recommended the use of Galapagos UK’s JYSELECA® (filgotinib) for eligible patients with severe active …


FDA turns down Gilead’s JAK inhibitor filgotinib in rheumatoid arthritis, endangering 2020 approval hopes

August 20, 2020
Research and Development, Sales and Marketing FDA, Gilead, filgotinib

Gilead’s JAK inhibitor filgotinib has been unexpectedly knocked back by the FDA as a therapy to treat moderately to severely …


Gilead’s filgotinib combos fall short in lupus and Sjögren’s syndrome

October 28, 2019
Research and Development, Sales and Marketing Gilead, Lupus, filgotinib, pharma

Gilead’s impending regulatory submission of its JAK inhibitor filgotinib to the FDA for the treatment of rheumatoid arthritis has been …


Gilead and Galapagos’ ankylosing spondylitis drug hits Phase 2 trial goal

September 7, 2018
Medical Communications, Research and Development Galapagos, Gilead, ankylosing spondylitis, filgotinib, pharma

Gilead and Galapagos have announced that their jointly-developed selective JAK1 inhibitor filgotinib has met its primary endpoint in a Phase …

Gilead sign

Gilead steps in to rescue Galapagos RA drug

December 18, 2015
Sales and Marketing AbbVie, Gilead, Gilead Sciences, filgotinib, inflammation, inflammatory diseases, rheumatoid arthritis

Gilead Sciences is to pay $725million for the rights to filgotinib, a JAK1-selective inhibitor for rheumatoid arthritis and other inflammatory …

Latest content